Search

Displaying results 3441 - 3450 of 10000 in total
  1. Drug

    Hydrogenated soybean oil

    go.drugbank.com/drugs/DB11302
    Approved

    According to the FDA, hydrogenated soybean oil is generally recognized as safe (GRAS) food substance. … It may be found in cosmetics and personal care products as an emollient or skin conditioning agent.

  2. Drug

    Dilmapimod

    go.drugbank.com/drugs/DB12140
    Investigational

    Previous p38 MAP-kinase inhibitors have been hindered in development by liver toxicity. Methotrexate (common treatment for RA patients) also has potential liver toxicity.} … Dilmapimod (SB-681323) is a p38 MAP-kinase inhibitor that has potential uses in inflammatory conditions such as RA (Rheumatoid Arthritis).

  3. Drug

    mRNA-1010

    go.drugbank.com/drugs/DB22484
    Approved

    [L64058] The FDA approved mFLUSIVA on August 5, 2026 for active immunization against influenza in adults 50 years of age and older, making it the first mRNA-based influenza vaccine approved in the United … benefit to be confirmed in a postmarketing trial.

  4. Drug

    CRx-401

    go.drugbank.com/drugs/DB05775
    Experimental

    Unlike other NSAIDs, or non-steroidal anti-inflammatory drugs, the dose of diflunisal in CRx-401 has demonstrated in preclinical studies the ability to synergistically enhance the anti-diabetic effects … In third-party clinical studies, the dose of bezafibrate contained in CRx-401 has been observed to have a positive impact on cellular pathways that influence glycemic and lipid profiles, and this dose

  5. Drug

    Amrinone

    go.drugbank.com/drugs/DB01427
    ApprovedWithdrawn

    Amrinone (or inamrinone) is a type 3 pyridine phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure.

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Lisocabtagene maraleucel

    go.drugbank.com/drugs/DB16582
    ApprovedInvestigational

    [L43322] In 2025, the FDA also approved lisocabtagene maraleucel as the first CAR T-cell therapy in the United States for adult patients with relapsed or refractory marginal zone lymphoma (MZL). … [A228493] Lisocabtagene maraleucel was granted FDA approval on 5 February 2021 [L31583] and EC approval on 5 April 2022.[L42210] It was later granted Health Canada approval on 6 May 2022.

  7. Drug

    Glasdegib

    go.drugbank.com/drugs/DB11978
    ApprovedInvestigational

    [A40310] Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML). … Currently, the current gold standard of AML in older patients is still venetoclax with hypomethylation agents, new clinical combinations of glasdegib are being tested in hope of replacing venetoclax due

  8. Drug

    Benzgalantamine

    go.drugbank.com/drugs/DB19353
    ApprovedInvestigational

    [L51564] Benzgalantamine was approved by the FDA in July 2024 for the treatment of mild-to-moderate dementia in Alzheimer's patients.[L51534,L51564] … Gastrointestinal adverse effects are the most frequently reported side effects in patients undergoing treatment with cholinesterase inhibitors, including galantamine, and are often a reason for treatment

  9. Drug

    Terconazole

    go.drugbank.com/drugs/DB00251
    Approved

    [A178093]Due to the existence of 2 stereocentres, there are 4 possible stereoisomers for terconazole. … Terconazole is an anti-fungal drug that is mainly used to treat vaginal yeast infections (or vaginal candidiasis). It is classified as a _triazole ketal derivative_.

  10. Drug

    Tamibarotene

    go.drugbank.com/drugs/DB04942
    Investigational

    Tamibarotene is currently approved in Japan for treatment of recurrent APL, and is undergoing clinical trials in the United States. … Tamibarotene is a novel synthetic retinoid for acute promyelocytic leukaemia (APL).